Colon Cancer

• EMA approval · 2025-05-05
  EMA Authorised: Ecansya (previously Capecitabine Krka) (capecitabine) — Krka, d.d., Novo mesto

  The EMA authorised Ecansya, a capecitabine product by Krka, as a new generic cancer treatment option for breast, colon, colorectal, and gast…

• EMA approval · 2025-05-02
  EMA Authorised: Xeloda (capecitabine) — CHEPLAPHARM Arzneimittel GmbH

  The EMA authorised CHEPLAPHARM Arzneimittel GmbH to market Xeloda (capecitabine) in the EU for several cancers, including breast, colon/colo…

• FDA approval · 2016-05-11
  FDA Approved: OXALIPLATIN — Original Application (Qilu Pharmaceutical Co., Ltd.)

  FDA approved Qilu Pharmaceutical Co., Ltd.'s generic oxaliplatin under Original Application (ANDA204616), providing a generic option for col…

• FDA approval · 2011-12-28
  FDA Approved: OXALIPLATIN — Supplemental Application (Winthrop U.S, a business of sanofi-aventis U.S. LLC)

  FDA approved a supplemental application for Oxaliplatin, a drug developed by Winthrop U.S, a business of sanofi-aventis U.S. LLC, indicating…